[go: up one dir, main page]

WO2018133547A1 - PROCÉDÉ DE CONSTRUCTION D'UNE BANQUE SERVANT À LA DÉTECTION PRÉNATALE NON INVASIVE DES MUTATIONS DE GÈNE DE LA β-THALASSÉMIE FŒTALE, PROCÉDÉ DE DÉTECTION ET KIT - Google Patents

PROCÉDÉ DE CONSTRUCTION D'UNE BANQUE SERVANT À LA DÉTECTION PRÉNATALE NON INVASIVE DES MUTATIONS DE GÈNE DE LA β-THALASSÉMIE FŒTALE, PROCÉDÉ DE DÉTECTION ET KIT Download PDF

Info

Publication number
WO2018133547A1
WO2018133547A1 PCT/CN2017/113233 CN2017113233W WO2018133547A1 WO 2018133547 A1 WO2018133547 A1 WO 2018133547A1 CN 2017113233 W CN2017113233 W CN 2017113233W WO 2018133547 A1 WO2018133547 A1 WO 2018133547A1
Authority
WO
WIPO (PCT)
Prior art keywords
primer set
upstream
downstream
specific
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2017/113233
Other languages
English (en)
Chinese (zh)
Inventor
王晓锋
徐湘民
曾华萍
宋卓
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetalks Bio-Tech (changsha) Co Ltd
Original Assignee
Genetalks Bio-Tech (changsha) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetalks Bio-Tech (changsha) Co Ltd filed Critical Genetalks Bio-Tech (changsha) Co Ltd
Publication of WO2018133547A1 publication Critical patent/WO2018133547A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms

Definitions

  • the invention relates to the field of gene detection technology, in particular to a method, a detection method and a kit for constructing a non-invasive prenatal fetal ⁇ -thalassemia gene mutation detection library.
  • Thalassemia (referred to as thalassemia) is one of the high incidence genetic diseases in the world. It is due to the mutation or deletion of human genes, resulting in an imbalance of the synthesis rate of ⁇ , ⁇ -globin peptide chains, resulting in hemolytic anemia.
  • Two common types of thalassaemia are ⁇ -thalassemia and ⁇ -thalassemia, ⁇ -thalassemia-related genes are HBA2 and HBA1, and ⁇ -thalassaemia-related genes are HBB.
  • the thalassemia is concentrated in the tropical and subtropical regions, mostly in the Mediterranean countries, followed by the Middle East, India, Pakistan, Southeast Asia, South China and North Africa. The United States is an immigrant country with a high incidence.
  • ⁇ -thalassemia genotypes are commonly found as - ⁇ SEA , - ⁇ 3.7, - ⁇ 4.2, ⁇ CS , ⁇ QS and ⁇ WS , and 26 gene mutations are common in ⁇ -thalassemia. do not. At present, there is no cure for thalassaemia. It can only rely on traditional methods of treatment, that is, blood transfusion therapy is the main method, and the price is expensive. Therefore, prenatal screening and diagnosis are of great significance for preventing such birth defects.
  • Chiu RW achieves efficient detection of the father-derived codons 41/42 4bp deletion by using real-time fluorescent PCR technology, and researchers have developed detection methods for other ⁇ -thalassaemia mutations, but since the detection mutations are mostly point mutations, The specificity of the method needs to be improved. Studies on alpha-thalassemia mutations have also been reported. Warunee Tungwiwat et al. established a method for detecting ⁇ 0 deletions based on real-time PCR, but the sensitivity of this method needs to be improved. In addition, a variety of high-sensitivity techniques have also been tried for non-invasive depletion detection, such as mass spectrometry, digital PCR, COLD-PCR, and the like.
  • the detection methods based on single-site PCR technology have certain limitations, such as low plasma DNA content and high fragmentation characteristics, which may bring false negative PCR.
  • This method can only detect the presence of a specific paternal mutation different from the mother, and cannot further determine the presence or absence of the maternal mutation.
  • Whole-genome sequencing or target region capture sequencing of maternal plasma free DNA based on high-throughput sequencing technology can more accurately detect fetal thalassemia genes, but the cost of genome-wide sequencing and the complexity of analytical methods and the need for parental monomers Types and the like limit the clinical application; target region capture sequencing can only achieve the differentiation of the fetal ⁇ SEA deletion pure heterozygous type due to the low capture efficiency of the target region, and there is also the possibility of typing errors. In view of this, it is necessary to provide a high-precision non-invasive prenatal fetal thalassemia gene mutation detection method.
  • the invention provides a method, a detection method and a kit for constructing a non-invasive fetal ⁇ -thalassemia gene mutation detection library, which can accurately and efficiently detect ⁇ -type thalassemia gene mutation, and the result is consistent with the amniocentesis detection type, but Safety, non-invasiveness and high efficiency are significantly better than amniocentesis.
  • the present invention provides a method for constructing a non-invasive prenatal fetal ⁇ -thalassemia gene mutation detection library for detecting non-invasive prenatal fetal ⁇ -thalassemia gene mutation by high-throughput sequencing
  • the above methods include:
  • the above upstream specific primer set 1 comprises an upstream primer set 1 for amplifying a ⁇ -thalassemia gene and an upstream primer set 1 for calculating a plurality of SNP sites of a fetal free DNA ratio;
  • the above-mentioned downstream specific primer set 1 comprising a downstream primer set 1 for amplifying a beta thalassemia gene and a downstream primer set 1 for calculating a plurality of SNP sites of a fetal free DNA ratio;
  • the upstream specific primer set 2 includes an upstream primer set 2 for amplifying a ⁇ -thalassemia gene and an upstream primer set 2 for calculating a plurality of SNP sites of a fetal free DNA ratio; the above-mentioned downstream specific primer set 2 comprising a downstream primer set 2 for amplifying a beta thalassemia gene and a downstream primer set 2 for calculating a plurality of SNP sites of a fetal free DNA ratio;
  • upstream specific primer set 2 is closer to the corresponding amplification target site than the upstream specific primer set 1, and the downstream specific primer set 2 is closer to the corresponding amplification than the downstream specific primer set 1 Target locus
  • the upstream specific primer set 2 and the 5' end of the downstream specific primer set 2 described above contain a linker sequence for a high throughput sequencing library
  • the upstream specific amplification product 2 and the downstream specific amplification product 2 are mixed, and then amplified using universal primers at both ends to obtain a library which can be sequenced by the machine.
  • the 5' end of the upstream specific primer set 1 and the downstream specific primer set 1 described above are provided with a modification for isolating the amplification product, preferably with a biotin modification.
  • the 3' end of the primer for the specific target site in the upstream specific primer set 1 and the 5' end of the primer corresponding to the target site in the upstream specific primer set 2 are 10-15 bases Coincident; the 3' end of the primer for the specific target site in the downstream specific primer set 1 and 10-15 bases from the 5' end of the primer for the target site in the downstream specific primer set 2 described above Coincident.
  • upstream primer set 1 sequence for amplifying the ⁇ -thalassemia gene is as shown in SEQ ID NOS: 1-7;
  • the upstream primer set 1 sequence of the above plurality of SNP sites for calculating the ratio of fetal free DNA is as shown in SEQ ID NOS: 8-17;
  • the sequence of the downstream primer set 1 for amplifying the ⁇ -thalassemia gene is shown in SEQ ID NOs: 18-25;
  • the above upstream primer set 2 sequence for amplifying the ⁇ -thalassaemia gene is shown in SEQ ID NOs: 36-42;
  • the upstream primer set 2 sequence of the above plurality of SNP sites for calculating the ratio of fetal free DNA is shown in SEQ ID NO: 43-52;
  • the sequence of the downstream primer set 2 for amplifying the ⁇ -thalassemia gene is shown in SEQ ID NOs: 53-59;
  • the sequence of the downstream primer set 2 of the above plurality of SNP sites for calculating the ratio of fetal free DNA is shown in SEQ ID NOs: 60-69.
  • the present invention provides a non-invasive prenatal fetal ⁇ -thalassemia gene mutation detecting method comprising performing high-throughput sequencing of a library constructed by the method of the first aspect to obtain a sequencing read read; Based on the total depth of the unique specific tag sequence of the site and the depth of the allele of the mutation, the fetal DNA content was calculated and the thalassemia-related mutation was typed to analyze the ⁇ -thalassemia gene mutation.
  • the present invention provides a non-invasive prenatal fetal ⁇ -thalassemia gene mutation detection library construction kit for performing non-invasive prenatal fetal ⁇ -thalassaemia gene mutation by high-throughput sequencing
  • the above kits include:
  • the above upstream specific primer set 1 comprises an upstream primer set 1 for amplifying a ⁇ -thalassemia gene and an upstream primer set 1 for calculating a plurality of SNP sites of a fetal free DNA ratio;
  • the above-mentioned downstream specific primer set 1 comprising a downstream primer set 1 for amplifying a beta thalassemia gene and a downstream primer set 1 for calculating a plurality of SNP sites of a fetal free DNA ratio;
  • upstream specific primer set 2 and downstream specific primer set 2 respectively, for specifically amplifying the above upstream specific amplification product 1 and downstream specific amplification product 1 respectively to obtain upstream specific expansion Product 2 and downstream specific amplification product 2,
  • the upstream specific primer set 2 includes an upstream primer set 2 for amplifying a ⁇ -thalassemia gene and an upstream primer set 2 for calculating a plurality of SNP sites of a fetal free DNA ratio; the above-mentioned downstream specific primer set 2 comprising a downstream primer set 2 for amplifying a beta thalassemia gene and a downstream primer set 2 for calculating a plurality of SNP sites of a fetal free DNA ratio;
  • the upstream specific primer set 2 is closer to the corresponding amplification target site than the upstream specific primer set 1, and the downstream specific primer set 2 is closer to the corresponding amplification than the downstream specific primer set 1 Target site; the upstream specific primer set 2 and the 5' end of the downstream specific primer set 2 described above contain a linker sequence for a high throughput sequencing library.
  • the 5' end of the upstream specific primer set 1 and the downstream specific primer set 1 described above are provided with a modification for isolating the amplification product, preferably with a biotin modification.
  • the 3' end of the primer for the specific target site in the upstream specific primer set 1 and the 5' end of the primer corresponding to the target site in the upstream specific primer set 2 are 10-15 bases Coincident; the 3' end of the primer for the specific target site in the downstream specific primer set 1 and 10-15 bases from the 5' end of the primer for the target site in the downstream specific primer set 2 described above Coincident.
  • upstream primer set 1 sequence for amplifying the ⁇ -thalassemia gene is as shown in SEQ ID NOS: 1-7;
  • the upstream primer set 1 sequence of the above plurality of SNP sites for calculating the ratio of fetal free DNA is as shown in SEQ ID NOS: 8-17;
  • the sequence of the downstream primer set 1 for amplifying the ⁇ -thalassemia gene is shown in SEQ ID NOs: 18-25;
  • the above upstream primer set 2 sequence for amplifying the ⁇ -thalassaemia gene is shown in SEQ ID NOs: 36-42;
  • the upstream primer set 2 sequence of the above plurality of SNP sites for calculating the ratio of fetal free DNA is shown in SEQ ID NO: 43-52;
  • the sequence of the downstream primer set 2 for amplifying the ⁇ -thalassemia gene is shown in SEQ ID NOs: 53-59;
  • the sequence of the downstream primer set 2 of the above plurality of SNP sites for calculating the ratio of fetal free DNA is shown in SEQ ID NOs: 60-69.
  • kit further includes:
  • the method and kit of the invention can construct a library for detection of ⁇ -thalassemia gene mutation by using maternal free plasma DNA as a raw material, and realize detection of ⁇ -type thalassemia gene mutation by high-throughput sequencing of the library.
  • the key is that in the library construction, a specific linker is ligated to the free DNA fragment of the maternal peripheral blood, and then the pre-amplification product of the linker ligated product is creatively divided into two parts, which are used independently for the target site (such as ⁇ -type thalassemia).
  • the upstream and downstream primers of the gene are subjected to two rounds of specific amplification, which can highly enrich the target site and significantly increase the specificity of primer amplification.
  • the upstream primer set and the downstream primer set for calculating a plurality of SNP sites of the fetal free DNA ratio are respectively used for amplification.
  • different primers are also used for the SNP site for two rounds of specificity.
  • Sexual amplification can efficiently and accurately calculate the fetal DNA content.
  • the fetal DNA content can be calculated based on the sequencing read length and the thalassemia-related mutations can be classified to effectively distinguish the mutations of the embryonic gene.
  • the inventors have designed highly efficient primers specifically for thalassemia genes, as well as primers for calculating multiple SNP sites of fetal DNA ratio.
  • the library construction method of the present invention it is preferable to accurately and efficiently detect the ⁇ -type thalassemia gene mutation using the primer sequence set provided by the present invention, and the result is consistent with the amniocentesis detection type, but the safety, Non-invasive and highly effective in terms of amniocentesis.
  • FIG. 1 is a schematic flow chart showing a method for constructing a non-invasive prenatal fetal ⁇ -thalassemia gene mutation detection library and a mutation detection method according to an embodiment of the present invention
  • FIG. 2 is a schematic diagram showing the relative positional relationship between the upstream and downstream specific primers, the universal primers and the template in the embodiment of the present invention
  • FIG. 3 is a pre-library (a) and a final library (b) for detecting non-invasive prenatal fetal ⁇ -thalassemia gene mutation according to an embodiment of the present invention; A 2% gel electrophoresis detection map, M for Marker, B1-B6 for 6 exemplary samples.
  • the method for constructing a non-invasive prenatal fetal ⁇ -thalassemia gene mutation detection library comprises the steps of:
  • S1 A linker sequence with a specific tag sequence and an optional sample tag sequence is ligated to the parental peripheral blood free DNA.
  • the parental peripheral blood free DNA that is, the peripheral blood free DNA of pregnant women, including maternal blood free DNA and fetal-derived free DNA.
  • the linker sequence carries a specific tag sequence, which can be a random sequence of n (eg, 8 or 10) bases in length, such that each linker sequence is different from the other linker sequences, that is, the linker sequence is
  • n eg, 8 or 10
  • the free DNA fragments of each parental blood bank have a specific linker sequence, which facilitates the differentiation of different maternal peripheral blood free DNA fragments in the sequence information analysis after subsequent sequencing.
  • sample pooling of different sources eg, peripheral blood free DNA from different maternal sources
  • linker sequence can also With a sample tag sequence (index), it is used to distinguish samples from different sources.
  • S2 Pre-library amplification of the ligation product of the previous step using a pre-library amplification primer sequence, wherein the pre-library amplification primer sequence is complementary to the linker sequence.
  • Pre-library amplification is performed to increase the amount of linker ligation product, as some of the molecules in the linker ligation product may have a lower copy number and are specifically amplified in subsequent partitions. At these times, these molecules with low copy number may not be efficiently amplified, and pre-amplification increases the amount of linker ligation products, so that molecules of various copy numbers can be efficiently amplified.
  • the pre-library obtained in the previous step is divided into an upstream pre-library and a downstream pre-library, and the upstream pre-library and the downstream pre-library are specifically amplified by using the upstream specific primer set 1 and the downstream specific primer set 1, respectively, respectively.
  • the pre-library is divided into an upstream pre-library and a downstream pre-library for two rounds of specific amplification, which can significantly increase the specificity of primer amplification.
  • the beneficial effects of separate independent amplification on the upstream and downstream include: on the one hand, upstream specific primers and downstream specific primers need to be closer to the amplification target site due to the second generation high-throughput sequencing read shorts (or Target region), it is difficult to effectively amplify the target fragment without separation, and independent amplification of the upstream and downstream can effectively amplify the target fragment; on the other hand, independent amplification of the upstream and downstream can retain the linker sequence at one end of the sequence. Facilitate the subsequent high-throughput sequencing.
  • the amplification target site includes a ⁇ -type thalassemia gene and a plurality of SNP sites for calculating the fetal DNA ratio
  • the upstream specific primer set 1 and the downstream specific Sex primer set 1 is also separately packaged
  • Two kinds of primers that is, the upstream specific primer set 1 includes: an upstream primer set 1 for amplifying a ⁇ -thalassemia gene, and an upstream primer set 1 for calculating a plurality of SNP sites of a fetal free DNA ratio
  • downstream specific The sex primer set 1 includes a downstream primer set 1 for amplifying a ⁇ -thalassemia gene and a downstream primer set 1 for calculating a plurality of SNP sites of a fetal free DNA ratio.
  • FIG 2 shows an upstream primer set 1 (USP1) for amplifying a ⁇ -thalassemia gene and a downstream primer set 1 (DSP1) for amplifying a ⁇ -thalassaemia gene in combination with a template in an embodiment of the present invention.
  • USP1 and DSP1 are located at the left and right sides of the amplification target site, or the detection site (ie, the ⁇ -type thalassemia gene mutation). Generally, the 3' end of USP1 and DSP1 are closer to the detection point.
  • the second-generation high-throughput sequencing reads shorter, such as about 100bp, if the USP1 and DSP1 3' end distance detection point In the far distance, it may be that the second generation high-throughput sequencing cannot effectively detect the detection points.
  • the relative positional relationship of the upstream and downstream specific primers to the template binding of the plurality of SNP sites for calculating the fetal DNA ratio is the same as that of the schematic diagram of FIG.
  • the 5' end of the upstream specific primer set 1 and the downstream specific primer set 1 may be provided with a modification for isolating the amplification product, preferably with Biotin modification, biotin can bind to avidin, so upstream specific amplification product 1 and downstream specific amplification product 1 can be separated from the reaction system by biotin-avidin affinity binding.
  • the specific primers used for the second round of specific primer amplification also include upstream specific primers and downstream specific primers.
  • the upstream specific primer set 2 used for the second round of specific primer amplification includes: an upstream primer set 2 for amplifying the ⁇ -type thalassemia gene And an upstream primer set 2 for calculating a plurality of SNP sites of the fetal free DNA ratio;
  • the downstream specific primer set 2 includes: a downstream primer set 2 for amplifying the ⁇ -thalassemia gene and for calculating a fetal free DNA ratio The downstream primer set 2 of multiple SNP sites.
  • Figure 2 shows an upstream primer set 2 (USP2) for amplifying a ⁇ -thalassemia gene and a downstream primer set 2 (DSP2) for amplifying a ⁇ -thalassaemia gene in combination with a template in an embodiment of the present invention.
  • USP2 upstream primer set 2
  • DSP2 downstream primer set 2
  • Relative positional relationship It can be seen that USP2 is closer to the ⁇ -type thalassemia gene mutation site than USP1, and DSP2 is closer to the ⁇ -type thalassemia gene mutation site than DSP1.
  • the relative positional relationship between the upstream and downstream primer set 2 and the template binding of the plurality of SNP sites for calculating the fetal free DNA ratio is the same as that of the schematic diagram of FIG.
  • the upstream specific primer set 2 is closer to the corresponding amplification target site than the upstream specific primer set 1
  • the downstream specific primer set 2 is closer to the corresponding amplification target site than the downstream specific primer set 1.
  • the primer for a specific target site in the upstream specific primer set 1 for example, USP1 for the ⁇ -type thalassemia gene
  • the upstream specific primer set 2 for the target site Primers eg, USP2 against the beta-type thalassemia gene
  • primers for a specific target site in the downstream specific primer set 1 eg, for beta-type thalassemia
  • the 3' end of the DSP1 of the gene has a 10-15 base overlap with the 5' end of the primer for the target site in the downstream specific primer set 2 (for example, DSP2 for the ⁇ -thalassaemia gene).
  • 3' end and “5' end” refer to a sequence near the 3' end and the 5' end, respectively. This coincidence is mainly considering that USP1 and DSP1 are close to the original detection point (for example, the ⁇ -type thalassemia gene mutation site), and the superposition of bases can fully utilize the binding space while further improving the amplification specificity.
  • upstream specific primer set 2 and downstream specific primer set 2 may contain a linker sequence for a high throughput sequencing library. Specifically, which high-throughput sequencing platform is used, the corresponding linker sequence of the platform is used.
  • the universal primer is capable of binding to the linker sequence and is amplified by universal primers to obtain a library for sequencing on the machine. Sequencing on the machine is achieved by high-throughput sequencing.
  • the high throughput sequencing technology can be selected from the group consisting of Illumina/Genome Analyzer/Hiseq/Miseq/NEXTseq CN500, Applied Biosystems SOLID, and life Technologies/Ion Torrent. Specifically, which high-throughput sequencing technology is used, universal primers also use primers corresponding to the high-throughput sequencing technology.
  • the upstream primer set 1 sequence for amplifying the beta thalassemia gene is as set forth in SEQ ID NOs: 1-7; upstream of a plurality of SNP sites for calculating fetal free DNA ratio
  • the primer set 1 sequence is shown in SEQ ID NOS: 8-17; the downstream primer set 1 sequence for amplifying the ⁇ -thalassemia gene is shown in SEQ ID NOs: 18-25; used to calculate the ratio of fetal free DNA
  • the downstream primer set 1 sequence of one SNP site is shown in SEQ ID NOs: 26-35; the upstream primer set 2 sequence for amplifying the ⁇ -thalassemia gene is shown in SEQ ID NOs: 36-42;
  • the upstream primer set 2 sequence of the plurality of SNP sites of the fetal free DNA ratio is shown in SEQ ID NO: 43-52; the downstream primer set 2 sequence for amplifying the ⁇ -thalassemia gene is SEQ ID NO: 53-59
  • the embodiment of the present invention further provides a non-invasive prenatal fetal ⁇ -thalassemia gene mutation detection method, which comprises performing high-throughput sequencing on a library constructed in the embodiment of the present invention to obtain a sequencing read length; and then, according to the unique position of the site The total depth of the specific tag sequence and the depth of the allele of the mutation, the fetal DNA content was calculated and the thalassemia-related mutation was typed to analyze the ⁇ -thalassemia gene mutation.
  • the embodiment of the invention further provides a kit for constructing a non-invasive prenatal fetal ⁇ -thalassemia gene mutation detection library, the above article
  • the library is used for the detection of non-invasive prenatal fetal ⁇ -thalassaemia gene mutations by high-throughput sequencing.
  • the above kits include:
  • upstream specific primer set 2 comprises an upstream primer set 2 for amplifying a ⁇ -thalassemia gene and an upstream of a plurality of SNP sites for calculating a fetal free DNA ratio Primer set 2; downstream specific primer set 2 includes a downstream primer set 2 for amplifying a ⁇ -thalassemia gene and a downstream primer set 2 for calculating a plurality of SNP sites of a fetal free DNA ratio.
  • upstream specific primer set 2 is closer to the corresponding amplification target site than the upstream specific primer set 1, and the downstream specific primer set 2 is closer to the corresponding amplification target site than the downstream specific primer set 1;
  • the 5' end of upstream specific primer set 2 and downstream specific primer set 2 contains a linker sequence for a high throughput sequencing library.
  • the upstream specific primer set 1 and the downstream specific primer set 1 have a modification for the isolation of the amplified product, preferably with a biotin modification, to separate upstream specific expansion from the system.
  • Product 1 and downstream specific amplification product 1 are added.
  • the 3' end of the primer for the specific target site in the upstream specific primer set 1 and the 10' end of the primer for the target site in the upstream specific primer set 2 are 10-15 Coincident of bases; the 3' end of the primer for the specific target site in the downstream specific primer set 1 and the 10' end of the primer of the downstream specific primer set 2 for the target site are 10-15 bases Coincident.
  • the upstream primer set 1 sequence for amplifying the beta thalassemia gene is as set forth in SEQ ID NOs: 1-7; upstream of a plurality of SNP sites for calculating fetal free DNA ratio
  • the primer set 1 sequence is shown in SEQ ID NOS: 8-17; the downstream primer set 1 sequence for amplifying the ⁇ -thalassemia gene is shown in SEQ ID NOs: 18-25; used to calculate the ratio of fetal free DNA
  • the downstream primer set 1 sequence of one SNP site is shown in SEQ ID NOs: 26-35; the upstream primer set 2 sequence for amplifying the ⁇ -thalassemia gene is shown in SEQ ID NOs: 36-42;
  • the upstream primer set 2 sequence of the plurality of SNP sites of the fetal free DNA ratio is shown in SEQ ID NO: 43-52; the downstream primer set 2 sequence for amplifying the ⁇ -thalassemia gene is SEQ ID NO: 53-59
  • the kit further comprises:
  • R3 linker sequence carrying a specific tag sequence and an optional sample tag sequence for ligation of maternal peripheral blood free DNA to obtain a ligation product
  • R4 a pre-library amplification primer sequence which is complementary to the above-described linker sequence for pre-library amplification of the above-described ligation product
  • R5 a universal primer for amplifying the mixed product after mixing the upstream specific amplification product 2 and the downstream specific amplification product 2 described above to obtain a library which can be sequenced on the machine.
  • the linker sequence is set forth in SEQ ID NOs: 71-72; the pre-library amplification primer sequences are set forth in SEQ ID NOs: 72-73; and the universal primers are set forth in SEQ ID NO: 74-75. Show.
  • the upstream primer and the downstream primer are located on the left and right sides of the detection point, respectively.
  • the 3' end of the ipsilateral specific primer 1 and the 5' end of the specific primer 2 have a 10-15 base overlap.
  • Specific primer 1 has a biotin modification at the 5' end.
  • the 5' end of specific primer 2 contains a linker sequence for a high throughput sequencing library. Specifically, the primer sequences are shown in Table 1.
  • ADT-R pGATCGGAAGAGC (SEQ ID NO: 71).
  • NNNNNNNN is a specific tag sequence
  • ATTAAGG is a sample tag sequence (index)
  • the above linker sequence needs to be annealed into a double strand.
  • pre-lib-primer-F CAAGCAGAAGACGGCATACGA (SEQ ID NO: 72);
  • pre-lib-primer-R GCTCTTCCGATCT (SEQ ID NO: 73).
  • Seq-lib-primer-F CAAGCAGAAGACGGCATACGA (SEQ ID NO: 74);
  • reaction 1 Free DNA end repair, and the reaction system (Reaction 1) was set as shown in Table 2.
  • reaction 2 The DNA fragment is ligated to the linker sequence carrying the specific tag sequence and the sample tag sequence, and the reaction system (Reaction 2) is shown in Table 3.
  • thermocycler 20 ° C, 15 min; 65 ° C, 10 min; 4 ° C preservation.
  • Reagent volume DNA purification product obtained by reaction 2 24 ⁇ L 2 ⁇ KAPA HiFi HotStart Ready Mix (Kapa Biosystems) 25 ⁇ L Pre-lib-primer Mix (SEQ ID NO: 72-73) 1 ⁇ L total capacity 50 ⁇ L
  • the final reaction product was purified by using 50 ⁇ L of XP beads, and quantification by Qubit, and 5 ⁇ L of the reaction product was detected by 2% gel electrophoresis. The results are shown in Fig. 3a, indicating that the pre-library was successfully constructed. Two aliquots of the pre-library were taken and named as the upstream pre-library and the downstream pre-library, respectively, and each 100 ng was subjected to the next amplification.
  • Each sample pre-library is an upstream pre-library and a downstream pre-library, respectively using the corresponding upstream and downstream specific primer 1 and specific primer 2, respectively, until the amplification of the upstream and downstream primers of each sample is combined when using universal primer amplification. And then use universal primers for amplification.
  • the PCR reaction procedure was as follows: 95 ° C, 10 min, 1 cycle; (95 ° C, 30 s, 62 ° C, 30 s, 72 ° C, 1 min) 20 cycles; 72 ° C, 7 min, 1 cycle; 4 ° C storage.
  • reaction product 5 ⁇ L was subjected to 2% agarose gel electrophoresis, and the remaining product was recovered by 1.2X XP, eluted with 24 ⁇ L of ultrapure water or an eluent, and the eluate was subjected to further amplification.
  • the PCR reaction procedure was as follows: 95 ° C, 10 min, 1 cycle; (95 ° C, 30 s, 62 ° C, 30 s, 72 ° C, 1 min) 15 cycles; 72 ° C, 7 min, 1 cycle; 4 ° C preservation.
  • the PCR reaction procedure was as follows: 98 ° C, 45 s, 1 cycle; (98 ° C, 15 s, 60 ° C, 30 s, 72 ° C, 30 s) 10 cycles; 72 ° C, 1 min, 1 cycle; 4 ° C preservation.
  • Illumina NEXTseq CN500 was subjected to 75PE sequencing.
  • the molecular tag set sequences were re-aligned to the reference genome (BWA MEM), the sequences surrounding Indel were re-aligned using GATK software, and SNP and small indels were detected using samtools software. Calculate the embryonic DNA content based on the total depth of the unique molecular tag set sequence of the locus and the depth of the associated SNP locus allele (allele), and Genotyping of fetal thalassemia-related SNPs and INDELs.
  • non-invasive prenatal thalassemia gene detection was performed on 6 pregnant women with type ⁇ thalassemia carriers, and the results are shown in Table 8 below.
  • results show that the non-invasive prenatal detection and the amniocentesis detection of the ⁇ -type thalassemia gene mutation are consistent in the embodiment of the present invention, indicating that the method of the present invention can accurately and efficiently detect the ⁇ -type thalassemia gene mutation, and the results and amniocentesis detection
  • the classification is consistent, but the safety, non-invasiveness and high efficiency are obviously superior to amniocentesis.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de construction d'une banque servant à la détection prénatale non invasive des mutations de gène de la β-thalassémie fœtale, un procédé de détection et un kit. Selon le procédé de construction de la banque, un lieur spécifique est ligaturé à un fragment d'ADN libre du sang périphérique maternel, puis un produit de pré-amplification d'un produit de ligature de lieur est divisé en deux parties ; deux cycles d'amplification de spécificité sont effectués indépendamment à l'aide, respectivement, d'une amorce amont et d'une amorce aval d'un site cible, le site cible pouvant être enrichi avec une spécificité élevée, ce qui permet d'améliorer considérablement la spécificité de l'amplification d'amorce. De plus, deux cycles d'amplification de spécificité sont effectués à l'aide des ensembles d'amorces amont et aval d'une pluralité de sites de SNP qui sont utilisés pour calculer la proportion d'ADN libre fœtal, la proportion d'ADN libre fœtal pouvant être calculée de manière efficace et précise. Le séquençage de la banque permet de détecter avec précision et efficacement des mutations de gène de β-thalassémie, ses résultats étant cohérents avec des classifications issues d'une détection par ponction de liquide amniotique, mais ledit procédé est considérablement supérieur à la détection par ponction de liquide amniotique en termes de sécurité, de non-invasivité et d'efficacité.
PCT/CN2017/113233 2017-01-19 2017-11-28 PROCÉDÉ DE CONSTRUCTION D'UNE BANQUE SERVANT À LA DÉTECTION PRÉNATALE NON INVASIVE DES MUTATIONS DE GÈNE DE LA β-THALASSÉMIE FŒTALE, PROCÉDÉ DE DÉTECTION ET KIT Ceased WO2018133547A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710044640.6A CN106755486A (zh) 2017-01-19 2017-01-19 无创产前胎儿β 型地贫基因突变检测文库构建方法、检测方法和试剂盒
CN201710044640.6 2017-01-19

Publications (1)

Publication Number Publication Date
WO2018133547A1 true WO2018133547A1 (fr) 2018-07-26

Family

ID=58945181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/113233 Ceased WO2018133547A1 (fr) 2017-01-19 2017-11-28 PROCÉDÉ DE CONSTRUCTION D'UNE BANQUE SERVANT À LA DÉTECTION PRÉNATALE NON INVASIVE DES MUTATIONS DE GÈNE DE LA β-THALASSÉMIE FŒTALE, PROCÉDÉ DE DÉTECTION ET KIT

Country Status (2)

Country Link
CN (1) CN106755486A (fr)
WO (1) WO2018133547A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106755486A (zh) * 2017-01-19 2017-05-31 人和未来生物科技（长沙）有限公司 无创产前胎儿β 型地贫基因突变检测文库构建方法、检测方法和试剂盒
CN108642160B (zh) * 2018-05-16 2022-03-11 广州市达瑞生物技术股份有限公司 检测胎儿地中海贫血致病基因的方法和试剂盒
CN110628891B (zh) * 2018-06-25 2024-01-09 深圳华大智造科技股份有限公司 一种对胚胎进行基因异常筛查的方法
CN113073135B (zh) * 2021-03-30 2024-02-23 人和未来生物科技（长沙）有限公司 一种检测耳聋基因的参考品及其制备方法与应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014029093A1 (fr) * 2012-08-23 2014-02-27 深圳华大基因科技有限公司 Procédé et système permettant de déterminer si une personne est dans un état anormal
CN104232777A (zh) * 2014-09-19 2014-12-24 天津华大基因科技有限公司 同时确定胎儿核酸含量和染色体非整倍性的方法及装置
CN104846089A (zh) * 2015-05-06 2015-08-19 厦门万基生物科技有限公司 一种孕妇外周血中胎儿游离dna比例的定量方法
CN104894279A (zh) * 2015-06-25 2015-09-09 北京嘉宝仁和医疗科技有限公司 α-地中海贫血基因突变检测试剂盒
CN106755486A (zh) * 2017-01-19 2017-05-31 人和未来生物科技（长沙）有限公司 无创产前胎儿β 型地贫基因突变检测文库构建方法、检测方法和试剂盒

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105861724B (zh) * 2016-06-03 2019-07-16 人和未来生物科技（长沙）有限公司 一种kras基因超低频突变检测试剂盒

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014029093A1 (fr) * 2012-08-23 2014-02-27 深圳华大基因科技有限公司 Procédé et système permettant de déterminer si une personne est dans un état anormal
CN104232777A (zh) * 2014-09-19 2014-12-24 天津华大基因科技有限公司 同时确定胎儿核酸含量和染色体非整倍性的方法及装置
CN104846089A (zh) * 2015-05-06 2015-08-19 厦门万基生物科技有限公司 一种孕妇外周血中胎儿游离dna比例的定量方法
CN104894279A (zh) * 2015-06-25 2015-09-09 北京嘉宝仁和医疗科技有限公司 α-地中海贫血基因突变检测试剂盒
CN106755486A (zh) * 2017-01-19 2017-05-31 人和未来生物科技（长沙）有限公司 无创产前胎儿β 型地贫基因突变检测文库构建方法、检测方法和试剂盒

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Non-official translation: Applied research of non-invasive prenatal diagnostic test for beta-thalassaemia using second generation sequencing technology on maternal plasma to track fetal free DNA", CHINA OUTSTANDING DOCTORAL DISSERTATIONS FULL-TEXT DATABASE, MEDICINE AND HEALTH TECHNOLOGY SERIES, 15 January 2015 (2015-01-15) *

Also Published As

Publication number Publication date
CN106755486A (zh) 2017-05-31

Similar Documents

Publication Publication Date Title
Varley et al. Dynamic DNA methylation across diverse human cell lines and tissues
WO2018133546A1 (fr) Procédé de construction, procédé de détection et kit pour une bibliothèque de détection de mutation de gène de thalassémie alpha fœtale prénatale non invasive
JP7334122B2 (ja) 妊娠高血圧腎症に特異的な循環ｒｎａシグネチャー
CN102533985B (zh) 一种检测dmd基因外显子缺失和/或重复的方法
CN116064753A (zh) 高效率的测序文库的构建方法及引物组和试剂盒
CN107177670A (zh) 一种高通量检测帕金森病致病基因突变的方法
CN108866207B (zh) 新型hiv-1耐药检测方法的建立及其应用
CN106011230A (zh) 用于检测碎片化dna目标区域的引物组合物及其应用
WO2018133547A1 (fr) PROCÉDÉ DE CONSTRUCTION D'UNE BANQUE SERVANT À LA DÉTECTION PRÉNATALE NON INVASIVE DES MUTATIONS DE GÈNE DE LA β-THALASSÉMIE FŒTALE, PROCÉDÉ DE DÉTECTION ET KIT
CN105296619A (zh) 中国人群肥胖易感基因snp分型用试剂盒及其使用方法
WO2017202389A1 (fr) Adaptateur approprié pour le séquençage d'ultratraces d'adn et application correspondante
CN111647953A (zh) 用于检测地中海贫血基因突变的高通量文库构建试剂盒及文库构建方法
CN103571822A (zh) 一种用于新一代测序分析的多重目的dna片段富集方法
CN110607363A (zh) 一种用于高通量检测糖尿病致病基因突变的核酸组及其试剂盒和应用
TW201321520A (zh) 用於病毒檢測的方法和系統
Ma et al. The analysis of ChIP-Seq data
CN104404128B (zh) 一种tert基因组合突变位点的检测试剂盒
CN114774517A (zh) 一种人免疫组库测序的方法及试剂盒
CN113699213A (zh) 一种用于二代测序文库构建方法及试剂盒
CN110734974B (zh) 一种癌症化疗用药snp位点组合以及检测引物
CN116769906B (zh) 用于检测α-地中海贫血的试剂盒
CN112501283B (zh) 卡马西平个体化用药基因的指导方法及试剂盒
CN109609694B (zh) 基于Illumina测序技术检测乙型肝炎分型及多耐药位点的试剂盒及方法
CN105543388A (zh) 基于21个线粒体snp位点的法医学快速检测试剂盒
CN117487932B (zh) 一种用于亲子鉴定的snp位点组合、及其检测引物对和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17892993

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 07/11/2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17892993

Country of ref document: EP

Kind code of ref document: A1